429 related articles for article (PubMed ID: 16430308)
1. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman S
Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
[TBL] [Abstract][Full Text] [Related]
2. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
[TBL] [Abstract][Full Text] [Related]
3. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.
Salem F; Johnson TN; Abduljalil K; Tucker GT; Rostami-Hodjegan A
Clin Pharmacokinet; 2014 Jul; 53(7):625-36. PubMed ID: 24671884
[TBL] [Abstract][Full Text] [Related]
4. Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
Brussee JM; Vet NJ; Krekels EHJ; Valkenburg AJ; Jacqz-Aigrain E; van Gerven JMA; Swart EL; van den Anker JN; Tibboel D; de Hoog M; de Wildt SN; Knibbe CAJ
Br J Clin Pharmacol; 2018 Feb; 84(2):358-368. PubMed ID: 29072785
[TBL] [Abstract][Full Text] [Related]
5. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
[TBL] [Abstract][Full Text] [Related]
6. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
Björkman S
Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
[TBL] [Abstract][Full Text] [Related]
7. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
Alcorn J; McNamara PJ
Clin Pharmacokinet; 2002; 41(13):1077-94. PubMed ID: 12403644
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
Johnson TN; Rostami-Hodjegan A; Tucker GT
Clin Pharmacokinet; 2006; 45(9):931-56. PubMed ID: 16928154
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
10. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
11. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
[TBL] [Abstract][Full Text] [Related]
12. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
[TBL] [Abstract][Full Text] [Related]
13. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults.
Ince I; de Wildt SN; Wang C; Peeters MY; Burggraaf J; Jacqz-Aigrain E; van den Anker JN; Tibboel D; Danhof M; Knibbe CA
Clin Pharmacokinet; 2013 Jul; 52(7):555-65. PubMed ID: 23512668
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
[TBL] [Abstract][Full Text] [Related]
15. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children.
Kanamori M; Takahashi H; Echizen H
Int J Clin Pharmacol Ther; 2002 Nov; 40(11):485-92. PubMed ID: 12698985
[TBL] [Abstract][Full Text] [Related]
16. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
17. Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.
Strougo A; Yassen A; Monnereau C; Danhof M; Freijer J
J Clin Pharmacol; 2014 Sep; 54(9):1006-15. PubMed ID: 24676942
[TBL] [Abstract][Full Text] [Related]
18. Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method.
Calvier EAM; Krekels EHJ; Johnson TN; Rostami-Hodjegan A; Tibboel D; Knibbe CAJ
AAPS J; 2019 Mar; 21(3):38. PubMed ID: 30850923
[TBL] [Abstract][Full Text] [Related]
19. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
20. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model.
Peeters MY; Allegaert K; Blussé van Oud-Alblas HJ; Cella M; Tibboel D; Danhof M; Knibbe CA
Clin Pharmacokinet; 2010 Apr; 49(4):269-75. PubMed ID: 20214410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
